Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production.

Th1 type cytokine responses are critical in the control of Mycobacterium tuberculosis infection. Recent findings indicate that 5-lipoxygenase-dependent (5-LO-dependent) lipoxins regulate host IL-12 production in vivo. Here, we establish lipoxins as key chemical mediators in resistance to M. tuberculosis infection. High levels of lipoxin A4 (LXA4) were detected in sera from infected WT but not infected 5-LO-deficient mice. Moreover, lungs from M. tuberculosis-infected 5-lo-/- animals showed increased IL-12, IFN-gamma, and NO synthase 2 (NOS2) mRNA levels compared with the same tissues in WT mice. Similarly, splenocyte recall responses were enhanced in mycobacteria-infected 5-lo-/- versus WT mice. Importantly, bacterial burdens in 5-lo-/- lungs were significantly lower than those from WT mice, and this enhancement in the resistance of the 5-lo-/- animals to M. tuberculosis was completely prevented by administration of a stable LXA4 analog. Together our results demonstrate that lipoxins negatively regulate protective Th1 responses against mycobacterial infection in vivo and suggest that the inhibition of lipoxin biosynthesis could serve as a strategy for enhancing host resistance to M. tuberculosis.

[1]  M. Arnaout,et al.  A synthetic eicosanoid LX‐mimetic unravels host‐donor interactions in allogeneic BMT‐induced GvHD to reveal an early protective role for host neutrophils , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  J. Aliberti Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma GONDII , 2005, Nature Reviews Immunology.

[3]  C. Serhan,et al.  Lipoxins and novel 15‐epi‐lipoxin analogs display potent anti‐inflammatory actions after oral administration , 2004, British journal of pharmacology.

[4]  A. Sher,et al.  MyD88-Deficient Mice Display a Profound Loss in Resistance to Mycobacterium tuberculosis Associated with Partially Impaired Th1 Cytokine and Nitric Oxide Synthase 2 Expression , 2004, Infection and Immunity.

[5]  A. Sher,et al.  Exogenous Pathogen and Plant 15-Lipoxygenase Initiate Endogenous Lipoxin A4 Biosynthesis , 2004, The Journal of experimental medicine.

[6]  A. Goldfeld Genetic susceptibility to pulmonary tuberculosis in Cambodia. , 2004, Tuberculosis.

[7]  O. Levy,et al.  Expression of BPI (bactericidal/permeability-increasing protein) in human mucosal epithelia. , 2003, Biochemical Society transactions.

[8]  Yu-Jin Jung,et al.  Increased interleukin‐10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice , 2003, Immunology.

[9]  A. Sher,et al.  Parasite-induced Lipoxin A4 Is an Endogenous Regulator of IL-12 Production and Immunopathology in Toxoplasma gondii Infection , 2002, The Journal of experimental medicine.

[10]  Yu-Jin Jung,et al.  Evidence Inconsistent with a Negative Influence of T Helper 2 Cells on Protection Afforded by a Dominant T Helper 1 Response against Mycobacterium tuberculosis Lung Infection in Mice , 2002, Infection and Immunity.

[11]  C. Serhan Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. , 2002, Prostaglandins & other lipid mediators.

[12]  O. Levy,et al.  Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Sher,et al.  Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity , 2002, Nature Immunology.

[14]  D. Rennick,et al.  Endogenous Inhibition of Antimycobacterial Immunity by IL‐10 Varies between Mycobacterial Species , 2001, Scandinavian journal of immunology.

[15]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[16]  C. Serhan,et al.  Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking1 , 2000, The Journal of Immunology.

[17]  G. Dai,et al.  Effects of modulating TGF-beta 1 on immune responses to mycobacterial infection in guinea pigs. , 1999, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  C. Clish,et al.  Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo , 1999 .

[19]  C. Serhan,et al.  Lipoxin (LX)A4 and Aspirin-triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor 1α–initiated Neutrophil Responses and Trafficking: Regulators of a Cytokine–Chemokine Axis , 1999, The Journal of experimental medicine.

[20]  F. Deist,et al.  Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. , 1998, Science.

[21]  J. Casanova,et al.  Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. , 1998, Science.

[22]  L. Dubé,et al.  A Randomized Controlled Trial Comparing Zileuton With Theophylline in Moderate Asthma , 1998 .

[23]  J. Mudgett,et al.  Identification of nitric oxide synthase as a protective locus against tuberculosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Dubé,et al.  Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. , 1997, The American journal of managed care.

[25]  M. Newport,et al.  Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. , 1996, The New England journal of medicine.

[26]  E. Israel,et al.  Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. , 1996, JAMA.

[27]  J. Flynn,et al.  IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. , 1995, Journal of immunology.

[28]  C. Lowenstein,et al.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. , 1995, Immunity.

[29]  Alan D. Roberts,et al.  The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. , 1995, Immunology.

[30]  C. Serhan,et al.  Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding. , 1985, Journal of immunology.